Minvest Partners News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Minvest partners. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Minvest Partners Today - Breaking & Trending Today

Epoch Investment Partners Inc. Boosts Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Epoch Investment Partners Inc. grew its holdings in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 82.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 589,070 shares of the medical research company’s stock after purchasing an additional 266,292 […] ....

United States , United Kingdom , Michaela Mussallem , Piper Sandler , Edwards Lifesciences , Scottb Ullem , Arlington Trust Co , United Kingdom Ltd , Epoch Investment Partners Inc , Telos Capital Management Inc , Goldman Sachs Group , Securities Exchange Commission , Edwards Lifesciences Co , Exchange Commission , Edwards Lifesciences Corporation , Epoch Investment Partners , Free Report , Investment Partners , Investment Management , Capital Management , Minvest Partners , Ninety One United Kingdom Ltd , One United Kingdom Ltd , Director Michael , Get Free Report , Lifesciences Corporation ,

Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by CIBC Private Wealth Group LLC

CIBC Private Wealth Group LLC grew its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 197.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,446,758 shares of the medical research company’s stock after acquiring […] ....

United Kingdom , United States , Michaela Mussallem , Stifel Nicolaus , Bernardj Zovighian , Edwards Lifesciences , Securities Exchange Commission , United Kingdom Ltd , Cibc Private Wealth Group , Edwards Lifesciences Corporation , Royal Bank , Wealth Group , Telos Capital Management Inc , Exchange Commission , Edwards Lifesciences Co , Arlington Trust Co , Edwards Lifesciences Company Profile , Free Report , Investment Management , Capital Management , Minvest Partners , Ninety One United Kingdom Ltd , One United Kingdom Ltd , Get Free Report , Director Michael , Lifesciences Corporation ,

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Sees Significant Increase in Short Interest

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Get Free Report) was the target of a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 7,090,000 shares, a growth of 5.5% from the April 30th total of 6,720,000 shares. Approximately 23.1% of the shares of the company […] ....

United States , Jeffrey Dierks , Cantor Fitzgerald , Harmony Biosciences Holdings Inc , Securities Exchange Commission , Charles Schwab Investment Management Inc , Needham Company , Harmony Biosciences Company Profile , Harmony Biosciences Holdings , Get Free Report , Harmony Biosciences , Exchange Commission , Minvest Partners , Schwab Investment Management , Capital Partners , Dark Forest Capital Management , Biosciences Holdings , Harmony Biosciences Daily ,

Needham & Company LLC Reiterates Buy Rating for Merus (NASDAQ:MRUS)

Needham & Company LLC reissued their buy rating on shares of Merus (NASDAQ:MRUS – Free Report) in a report released on Friday morning, Benzinga reports. Needham & Company LLC currently has a $66.00 target price on the biotechnology company’s stock. A number of other analysts also recently commented on the company. Truist Financial started coverage […] ....

United States , Stifel Nicolaus , William Blair , Needham Company , Swiss National Bank , Merus Company Profile , Free Report , Moderate Buy , Get Free Report , Minvest Partners , Capital Partners , Bay Capital Management , National Bank , Merus Daily ,

Needham & Company LLC Lowers Cytokinetics (NASDAQ:CYTK) Price Target to $72.00

Cytokinetics (NASDAQ:CYTK – Free Report) had its price target reduced by Needham & Company LLC from $108.00 to $72.00 in a research report report published on Thursday, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. CYTK has been the subject of several other research reports. JMP Securities lowered their price […] ....

Johnt Henderson , Fady Ibraham Malik , Victory Capital Management Inc , Vanguard Group Inc , Securities Exchange Commission , Legato Capital Management , Cytokinetics Company Profile , Needham Company , Cytokinetics Incorporated , Free Report , Moderate Buy , Get Free Report , Ibraham Malik , Exchange Commission , Director John , Minvest Partners , Capital Management , Victory Capital Management , Cytokinetics Daily ,